A detailed history of Rafferty Asset Management, LLC transactions in Arcus Biosciences, Inc. stock. As of the latest transaction made, Rafferty Asset Management, LLC holds 84,194 shares of RCUS stock, worth $1.23 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
84,194
Previous 95,792 12.11%
Holding current value
$1.23 Million
Previous $1.46 Million 11.73%
% of portfolio
0.0%
Previous 0.01%

Shares

18 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

SELL
$13.69 - $18.01 $158,776 - $208,879
-11,598 Reduced 12.11%
84,194 $1.29 Million
Q2 2024

Aug 13, 2024

SELL
$14.59 - $18.48 $3.56 Million - $4.51 Million
-243,875 Reduced 71.8%
95,792 $1.46 Million
Q1 2024

May 13, 2024

BUY
$14.83 - $20.18 $1.31 Million - $1.78 Million
88,263 Added 35.11%
339,667 $6.41 Million
Q4 2023

Feb 13, 2024

SELL
$13.43 - $19.63 $554,712 - $810,797
-41,304 Reduced 14.11%
251,404 $4.8 Million
Q3 2023

Nov 13, 2023

SELL
$17.62 - $23.54 $130,458 - $174,290
-7,404 Reduced 2.47%
292,708 $5.25 Million
Q2 2023

Aug 11, 2023

SELL
$16.97 - $22.03 $1.88 Million - $2.44 Million
-110,880 Reduced 26.98%
300,112 $6.1 Million
Q1 2023

May 11, 2023

BUY
$15.96 - $23.15 $3.45 Million - $5 Million
215,967 Added 110.74%
410,992 $7.5 Million
Q4 2022

Feb 13, 2023

SELL
$19.7 - $35.71 $662,235 - $1.2 Million
-33,616 Reduced 14.7%
195,025 $4.03 Million
Q3 2022

Nov 14, 2022

BUY
$23.23 - $30.07 $1.71 Million - $2.21 Million
73,585 Added 47.46%
228,641 $5.98 Million
Q2 2022

Aug 12, 2022

SELL
$17.23 - $37.73 $111,960 - $245,169
-6,498 Reduced 4.02%
155,056 $3.93 Million
Q1 2022

May 13, 2022

BUY
$28.92 - $41.83 $1.02 Million - $1.47 Million
35,236 Added 27.89%
161,554 $5.1 Million
Q4 2021

Feb 10, 2022

BUY
$31.38 - $48.47 $1.38 Million - $2.13 Million
43,988 Added 53.43%
126,318 $5.11 Million
Q3 2021

Nov 10, 2021

SELL
$26.93 - $37.68 $605,090 - $846,631
-22,469 Reduced 21.44%
82,330 $2.87 Million
Q2 2021

Aug 10, 2021

BUY
$22.75 - $35.77 $304,781 - $479,210
13,397 Added 14.66%
104,799 $2.88 Million
Q1 2021

May 10, 2021

BUY
$26.16 - $41.39 $2.01 Million - $3.18 Million
76,742 Added 523.48%
91,402 $2.57 Million
Q4 2020

Feb 10, 2021

SELL
$17.0 - $32.36 $946,679 - $1.8 Million
-55,687 Reduced 79.16%
14,660 $381,000
Q3 2020

Nov 13, 2020

BUY
$17.14 - $25.47 $934,489 - $1.39 Million
54,521 Added 344.5%
70,347 $1.21 Million
Q2 2020

Aug 07, 2020

BUY
$13.97 - $36.56 $221,089 - $578,598
15,826 New
15,826 $392,000

Others Institutions Holding RCUS

About Arcus Biosciences, Inc.


  • Ticker RCUS
  • Exchange NYSE
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 72,160,000
  • Market Cap $1.05B
  • Description
  • Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. Its product pipeline includes, Etrumadenant, a dual A2a/A2b adenosine receptor antagonist, which is in a Phase 1b/2 clinical trial; and Zimberelimab, an anti-PD-1 antibody that is in Phase 1b clinical trial for ...
More about RCUS
Track This Portfolio

Track Rafferty Asset Management, LLC Portfolio

Follow Rafferty Asset Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rafferty Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Rafferty Asset Management, LLC with notifications on news.